We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK REVISES WARNING LABELS ON PAXIL, WELLBUTRIN
GSK REVISES WARNING LABELS ON PAXIL, WELLBUTRIN
June 22, 2004
GlaxoSmithKline (GSK) has strengthened the warning labels on two of its antidepressant drugs -- a move that follows an FDA public health advisory in March that recommended closer monitoring of patients being treated with antidepressants.